Drug comparisons
Erenumab vs Ubrogepant
Compare Erenumab (Aimovig injection for prevention) vs Ubrogepant (Ubrelvy oral for acute migraines). Both CGRP antagonists with different roles and uses.
No comparison dimensions are available for this page.
Clinical context
This comparison occurs when evaluating CGRP-targeted options to distinguish monthly preventive therapy from on-demand acute migraine treatment.
Bottom line
Erenumab and Ubrogepant are complementary CGRP therapies rather than direct competitors, with choice driven by prevention versus acute-relief goals.
All medication comparisons